Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease
Figure 2
Effect of rosiglitazone
treatment on plasma levels of soluble ICAM-1 (sICAM-1) (a) and P-selectin
(sP-selectin) (b) in patients with diabetes and coronary artery disease after percutaneous coronary intervention.
Data are medians and ranges. Control group, ; rosiglitazone (RSG) group, .